Funding for this research was provided by:
National Institute on Aging (AG055184)
National Center for Advancing Translational Sciences (UL1TR002243, TR000445)
American Heart Association (18SFRN34110369)
Received: 26 August 2019
Accepted: 31 December 2019
First Online: 6 January 2020
Ethics approval and consent to participate
: The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.
: Not applicable.
: JCF, LMP, and JAR are employed by and NNA is co-founder and part owner of MTI BioTech Inc., which has executed an agreement for the rights to license the intellectual property for 2-hydroxybenzylamine from Vanderbilt University. WSA received payment for the clinical pharmacokinetic analysis.